January 4, 2019
Promedior’s PRM-151 for Idiopathic Pulmonary Fibrosis positioned as a Phase 3-ready candidate
Maker of fibrosis therapeutics, Promedior, said has agreed with the U.S. Food and Drug Administration (FDA) for registration, on the design of the study of PRM-151, a novel investigational anti-fibrotic immunomodulator, in patients with Idiopathic Pulmonary Fibrosis (IPF).